AACE endocrinology and diabetes最新文献

筛选
英文 中文
Craniopharyngioma Across the Lifespan: A Large Single-Center Cohort Study of Surgical Outcomes, Endocrine Morbidity, and Long-Term Disease Control. 颅咽管瘤贯穿整个生命周期:一项关于手术结果、内分泌发病率和长期疾病控制的大型单中心队列研究。
AACE endocrinology and diabetes Pub Date : 2026-08-03 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.015
Vivek Jha, Anand Sudhay, Ashutosh Rai, Debajyoti Chatterjee, Uma Nahar Saikia, Shivasanmugam Dhandapani, Sandeep Mohindra, S K Sahoo, Apinderpreet Singh, Mohammed Safeer V S, Manjul Tripathi, Vaishali Kaur, Amal Shaharyar, Pravin Salunke, Pinaki Dutta
{"title":"Craniopharyngioma Across the Lifespan: A Large Single-Center Cohort Study of Surgical Outcomes, Endocrine Morbidity, and Long-Term Disease Control.","authors":"Vivek Jha, Anand Sudhay, Ashutosh Rai, Debajyoti Chatterjee, Uma Nahar Saikia, Shivasanmugam Dhandapani, Sandeep Mohindra, S K Sahoo, Apinderpreet Singh, Mohammed Safeer V S, Manjul Tripathi, Vaishali Kaur, Amal Shaharyar, Pravin Salunke, Pinaki Dutta","doi":"10.1016/j.aed.2026.07.015","DOIUrl":"10.1016/j.aed.2026.07.015","url":null,"abstract":"<p><strong>Objective: </strong>Craniopharyngiomas are rare epithelial tumors of the sellar-suprasellar region associated with significant neurologic, endocrine, and metabolic morbidity. Long-term outcome data across the lifespan from low- and middle-income settings remain limited. We aimed to characterize clinical presentation, surgical outcomes, endocrine morbidity, mortality, long-term disease control, and the safety of growth hormone therapy.</p><p><strong>Methods: </strong>This retrospective observational study included patients with histologically confirmed craniopharyngioma managed at a tertiary-care center. Clinical, biochemical, radiologic, surgical, histopathologic, and follow-up data were analyzed. Tumors were classified as adamantinomatous or papillary. Surgical approaches, complications, tumor progression, endocrine outcomes, retreatment, mortality, and growth hormone therapy-related outcomes were evaluated.</p><p><strong>Results: </strong>A total of 274 patients were included (266 adamantinomatous, 8 papillary), with a median age at diagnosis of 16 years (range, 1-75 years). Headache or symptoms of increased intracranial pressure (88.0%) and visual impairment (77.4%) were the most common presenting features. Preoperative anterior pituitary dysfunction was present in 81.5% of patients. Median tumor volume was 17.0 cm<sup>3</sup>, with 20% classified as giant tumors. Residual or progressive disease occurred in 62.6% of patients, and 32.1% required retreatment. Postoperative anterior pituitary deficiency occurred in 98.1% and immediate postoperative arginine vasopressin deficiency in 90.1% of patients, and obesity was frequent during follow-up. Tumor progression did not differ between surgical approaches; however, cerebrospinal fluid-related complications were more frequent after transsphenoidal surgery. Thirty-three deaths occurred during follow-up. Rare presentations included cerebellar ataxia, bobble-head doll syndrome, malignant transformation, ectopic tumors, inflammatory pituitary pathology, and refractory disease.</p><p><strong>Conclusion: </strong>Craniopharyngioma is associated with substantial lifelong morbidity despite benign histology. Multidisciplinary, risk-adapted management strategies prioritizing functional preservation and long-term endocrine care are essential.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"801-813"},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Snyder-Robinson Syndrome Presenting With Severe Osteoporosis and Fragility Fracture: A Case Report and Literature Review. Snyder-Robinson综合征表现为严重骨质疏松和脆性骨折:1例报告和文献复习。
AACE endocrinology and diabetes Pub Date : 2026-07-31 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.012
Ana Cristina Macías, Marilyn Arosemena
{"title":"Snyder-Robinson Syndrome Presenting With Severe Osteoporosis and Fragility Fracture: A Case Report and Literature Review.","authors":"Ana Cristina Macías, Marilyn Arosemena","doi":"10.1016/j.aed.2026.07.012","DOIUrl":"10.1016/j.aed.2026.07.012","url":null,"abstract":"<p><strong>Background/objective: </strong>Snyder-Robinson syndrome (SRS) is an extremely rare X-linked genetic disorder caused by mutations in the spermine synthase (SMS) gene. SMS gene encodes SMS enzyme which is essential for producing spermine, a polyamine that plays a crucial role in various cellular functions like growth and repair. Patients often present with intellectual disability, hypotonia, seizures, scoliosis, and progressive bone fragility.</p><p><strong>Case report: </strong>We report the case of a 22-year-old male who presented with multiple fragility fractures and osteogenesis imperfecta-like features that was ultimately confirmed to have SRS.</p><p><strong>Discussion: </strong>Despite long-term bisphosphonate therapy, the patient developed more fragility fractures and transitioned to anabolic therapy with abaloparatide with stable laboratory parameters and no new interval fractures.</p><p><strong>Conclusion: </strong>This case highlights the endocrine-related manifestations of the syndrome, therapeutic challenges, and the importance of multidisciplinary management in rare metabolic bone disorders.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"832-836"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatide for Severe Obesity in Adolescents Without Diabetes. 替西帕肽治疗非糖尿病青少年严重肥胖。
AACE endocrinology and diabetes Pub Date : 2026-07-31 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.013
Reham Yehia, Priya Patel, Emily Sousa, Alaina P Vidmar
{"title":"Tirzepatide for Severe Obesity in Adolescents Without Diabetes.","authors":"Reham Yehia, Priya Patel, Emily Sousa, Alaina P Vidmar","doi":"10.1016/j.aed.2026.07.013","DOIUrl":"10.1016/j.aed.2026.07.013","url":null,"abstract":"<p><strong>Background/objective: </strong>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction in adults but remains unapproved for obesity treatment in adolescents without diabetes. The objective of this report is to describe adolescents with severe obesity without diabetes treated with tirzepatide, highlighting body mass index reduction (BMI), metabolic outcomes, and tolerability in a safety-net setting.</p><p><strong>Case presentation: </strong>Five adolescents (ages 11-16 years; 3 males, 2 females) presented with severe obesity (BMI 37-52 kg/m<sup>2</sup>; ≥120% of the 95th percentile). Baseline percent of the 95<sup>th</sup> percentile BMI (%BMI<sub>p95</sub>) ranged from 125% to 200%. Tirzepatide was initiated at 2.5 mg weekly and titrated to 10 to 15 mg. Over 6 to 18 months, %BMI<sub>p95</sub> decreased across all patients, with reductions from baseline to 18 months of 190% to 158%, 200% to 145%, 150% to 85%, and 135% to 85%; one patient decreased from 125% to 85% by 12 months. These changes corresponded to absolute weight reductions of 17.6 to 40 kg (13%-36%). Hemoglobin A1c decreased or remained within the normal range (4.3%-5.6%), triglycerides declined, and alanine aminotransferase normalized. No hypoglycemia or pancreatitis occurred. No treatment discontinuations were documented during available follow-up.</p><p><strong>Discussion: </strong>Marked weight reduction and metabolic improvement observed in these youth with obesity, without type 2 diabetes are consistent with outcomes reported in adult populations receiving tirzepatide, with greater weight loss associated with improved cardiometabolic parameters.</p><p><strong>Conclusion: </strong>This series highlights substantial weight reduction among adolescents with severe obesity treated with tirzepatide. Participants tolerated therapy during observed follow-up without reported gastrointestinal adverse effects, supporting further investigation in pediatric populations.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"837-841"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Early-Onset Osteoporosis and Fragility Fractures in a Young Male With Chronic Recurrent Multifocal Osteomyelitis Within the SAPHO Spectrum. 严重早发性骨质疏松和脆性骨折的年轻男性慢性复发性多灶性骨髓炎在SAPHO频谱。
AACE endocrinology and diabetes Pub Date : 2026-07-29 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.009
Sani Yasnain, Sandhya Shanthosh Kumar, Dur E Shahwar, Saira Tanveer, Ezza Wasim, Niveditha Manivannan
{"title":"Severe Early-Onset Osteoporosis and Fragility Fractures in a Young Male With Chronic Recurrent Multifocal Osteomyelitis Within the SAPHO Spectrum.","authors":"Sani Yasnain, Sandhya Shanthosh Kumar, Dur E Shahwar, Saira Tanveer, Ezza Wasim, Niveditha Manivannan","doi":"10.1016/j.aed.2026.07.009","DOIUrl":"10.1016/j.aed.2026.07.009","url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis in young adults warrants evaluation for secondary causes. SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is rare. Severe osteoporosis with fragility fractures as a presenting manifestation of chronic recurrent multifocal osteomyelitis/SAPHO syndrome is exceedingly rare.</p><p><strong>Case report: </strong>A 26-year-old man with normal body mass index, no tobacco or alcohol use, and regular physical activity presented with severe osteoporosis after low-trauma fractures of the left arm and L2 and L4 vertebrae following 5 years of back, hip, anterior chest wall pain, and axial stiffness. Initial DXA showed bone mineral density below the expected range for age (lumbar spine Z-score -3.0). Imaging demonstrated sternoclavicular marrow edema, multifocal radiotracer uptake, and bilateral sacroiliitis. Laboratory evaluation showed elevated ESR, CRP, IgA, and HLA-B27 positivity; available metabolic bone evaluation was otherwise unrevealing. Genetic testing identified an ALPK1 variant of uncertain significance. Isolated axial spondyloarthritis, infection, and malignancy were less likely because of multifocal sterile osteitis, anterior chest wall involvement, chronic course, and absence of systemic infectious or malignant features. He received adalimumab and completed 3 pamidronate infusion cycles. Through 2026 follow-up, ESR/CRP normalized on 3 checks, back pain resolved, no interim falls or fractures occurred, lumbar fractures showed radiographic healing, and repeat DXA was clinically stable.</p><p><strong>Discussion: </strong>Chronic recurrent multifocal osteomyelitis/SAPHO syndrome may cause secondary osteoporosis through inflammation-mediated osteoclast activation and impaired bone formation.</p><p><strong>Conclusion: </strong>Consider autoinflammatory bone disease in young adults with unexplained osteoporosis, fragility fractures, axial symptoms, anterior chest wall pain, or sacroiliitis.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"814-818"},"PeriodicalIF":0.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring LEPR Gene rs1137100 and rs1137101 Polymorphisms in Gestational Diabetes Mellitus: A Pilot Study From Bangladesh. 妊娠期糖尿病患者LEPR基因rs1137100和rs1137101多态性的初步研究
AACE endocrinology and diabetes Pub Date : 2026-07-24 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.008
Tania Tofail, Siratul Kubra Shifat, Farhana Sayeed, Mashfiqul Hasan, U S Mahzabin Amin, Muhammad Abul Hasanat
{"title":"Exploring LEPR Gene rs1137100 and rs1137101 Polymorphisms in Gestational Diabetes Mellitus: A Pilot Study From Bangladesh.","authors":"Tania Tofail, Siratul Kubra Shifat, Farhana Sayeed, Mashfiqul Hasan, U S Mahzabin Amin, Muhammad Abul Hasanat","doi":"10.1016/j.aed.2026.07.008","DOIUrl":"10.1016/j.aed.2026.07.008","url":null,"abstract":"<p><strong>Introduction: </strong>Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication that negatively impacts both the mother and the fetus. Leptin (LEP), a key regulator of glucose metabolism during pregnancy, is influenced by genetic factors. The rs1137101 single-nucleotide polymorphism (SNP) results in a glutamine-to-arginine substitution at position 223 in the LEP receptor, potentially affecting maternal and fetal metabolic outcomes.</p><p><strong>Methods: </strong>The study investigates the association of rs1137100 and rs1137101 polymorphisms in the LEPR gene with GDM. A total of 38 women with GDM and 72 controls were enrolled based on the WHO 2013 criteria, regardless of gestational age. Fasting insulin and LEP were measured using chemiluminescence immunoassay. Genetic samples were stored in ethylenediaminetetraacetic acid tubes, and genotyping of LEPR rs1137100 and rs1137101 was performed using Sanger sequencing. SNP analysis was done with SNPStats.</p><p><strong>Results: </strong>Fasting insulin (μIU/L) [GDM: 9.09 (4.18-14) vs normal glucose tolerance: 7.48 (3.06-11.9); <i>P</i> = 0.015] and LEP (ng/ml) [GDM: 170 (57.5-282.5) vs normal glucose tolerance: 118.4 (47.7-189.1); <i>P</i> = 0.031] levels were significantly elevated in GDM cases. Genotype frequencies of rs1137100 and rs1137101 showed no significant differences between GDM and controls (<i>P</i> > 0.05). Multivariate logistic regression under multiple genetic models also revealed no significant association. Linkage disequilibrium analysis indicated that the SNPs are not in linkage disequilibrium (D = -0.066, D' = 0.651, r2 = 0.106; <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>This small pilot study found no statistically significant association of rs1137100 and rs1137101 polymorphisms in the LEPR gene with GDM in this Bangladeshi population cohort.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"741-749"},"PeriodicalIF":0.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Hyperglycemia due to Calibration Misuse in an Eversense-365 Implantable Continuous Glucose Monitoring System. Eversense-365植入式连续血糖监测系统中校准不当导致的严重高血糖。
AACE endocrinology and diabetes Pub Date : 2026-07-23 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.007
Jennifer Moeller
{"title":"Severe Hyperglycemia due to Calibration Misuse in an Eversense-365 Implantable Continuous Glucose Monitoring System.","authors":"Jennifer Moeller","doi":"10.1016/j.aed.2026.07.007","DOIUrl":"10.1016/j.aed.2026.07.007","url":null,"abstract":"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) systems have transformed diabetes management by improving glycemic outcomes and providing real-time glucose data. Accuracy is commonly assessed by using metrics such as mean absolute relative difference. Implantable CGM systems, including Eversense-365, have demonstrated high accuracy and safety when used in accordance with recommended protocols.</p><p><strong>Objective: </strong>To describe a case of clinically significant CGM inaccuracy resulting from improper user calibration and to highlight associated safety implications.</p><p><strong>Case report: </strong>An adult with a 24-year history of type 1 diabetes complicated by microvascular and macrovascular disease, hypoglycemia unawareness, and mild cognitive impairment was using an implantable CGM system. Initially, sensor readings closely matched capillary glucose values when appropriate fingerstick calibration techniques were followed. However, the patient subsequently used CGM-derived glucose values in place of capillary measurements for calibration. This practice led to progressively inaccurate sensor readings, yielding falsely reassuring glucose values and delaying recognition of clinically significant hyperglycemia.</p><p><strong>Discussion: </strong>This case highlights a critical safety consideration in implantable CGM systems that rely on user-dependent calibration. Even with otherwise high-performing technology, improper calibration practices can significantly compromise accuracy. As CGM systems become increasingly integrated into automated insulin delivery platforms, user-related factors may introduce risk if proper technique is not consistently followed.</p><p><strong>Conclusion: </strong>Improper calibration of implantable CGM systems can lead to clinically significant inaccuracies and delayed recognition of hyperglycemia. Reinforcing patient education, adhering to recommended calibration protocols, and selecting patients thoughtfully are essential to ensure the safe and effective use of these devices.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"732-734"},"PeriodicalIF":0.0,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmune-mediated Primary Adrenal Insufficiency After Covid-19. Covid-19后自身免疫介导的原发性肾上腺功能不全。
AACE endocrinology and diabetes Pub Date : 2026-07-09 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.06.017
Jessica Naredo Rojas, Alberto Moscona-Nissan, Beverly Udegbe, Ilan Remba-Shapiro, Risa Waki, Sara L Stockman, Lisa B Nachtigall
{"title":"Autoimmune-mediated Primary Adrenal Insufficiency After Covid-19.","authors":"Jessica Naredo Rojas, Alberto Moscona-Nissan, Beverly Udegbe, Ilan Remba-Shapiro, Risa Waki, Sara L Stockman, Lisa B Nachtigall","doi":"10.1016/j.aed.2026.06.017","DOIUrl":"10.1016/j.aed.2026.06.017","url":null,"abstract":"<p><strong>Objective: </strong>Isolated cases of autoimmune-mediated primary adrenal insufficiency (PAI) after COVID-19 have been reported. However, the association has not been well characterized. The objective of this study is to determine the association and clinical characteristics of autoimmune-mediated PAI in patients following COVID-19.</p><p><strong>Case report: </strong>We identified patients with autoimmune-mediated PAI following recent COVID-19 illness from a large database and performed a retrospective chart review to analyze their clinical and biochemical presentation. Prior reported cases were reviewed. Inclusion criteria were biochemical confirmation and clinical features of PAI occurring within 12 months after COVID-19 illness, and evidence of autoimmune etiology. We identified 6 novel autoimmune-mediated PAI cases associated with COVID-19, out of 138 052 cases of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction. Eleven cases from the literature were added for a total of 17 patients (58.8% male and 41.2% female). Twelve (70.6%) were <30 years old. Five (29.4%) had a family history of autoimmune conditions. Five (29.4%) had prior autoimmune disease. The median time to PAI diagnosis was 21(9-151) days after SARS-CoV-2 infection. Median serum morning cortisol level was 1.0 (0.5-2.56) μg/dL. Mean serum adrenocorticotropin was 1212.6 ± 599.8 pg/mL, 19.7 ± 11.3 × upper limit of normal. Adrenal atrophy was present in 64%; 21-hydroxylase antibodies were positive in 100% (<i>n</i> = 16) of patients tested.</p><p><strong>Discussion: </strong>This is the largest original case series of autoimmune-mediated PAI associated with COVID-19 to date. Severe illness and/or SARS-CoV-2 viral infection may precipitate autoimmune-mediated PAI in susceptible patients.</p><p><strong>Conclusion: </strong>Awareness of autoimmune-mediated PAI occurring after COVID-19 is critical for the prevention of adrenal crisis in this context.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"783-787"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Need for Clinician Communication Strategies for Eating Disorders/Insulin Restriction in Type 1 Diabetes. 1型糖尿病患者饮食失调/胰岛素限制的临床沟通策略需求
AACE endocrinology and diabetes Pub Date : 2026-07-09 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.004
Heather L Stuckey, Candace R Bordner, Amie L Prokop, Elena Toschi, Ann E Goebel-Fabbri, Lori M Laffel
{"title":"The Need for Clinician Communication Strategies for Eating Disorders/Insulin Restriction in Type 1 Diabetes.","authors":"Heather L Stuckey, Candace R Bordner, Amie L Prokop, Elena Toschi, Ann E Goebel-Fabbri, Lori M Laffel","doi":"10.1016/j.aed.2026.07.004","DOIUrl":"10.1016/j.aed.2026.07.004","url":null,"abstract":"<p><p>Disordered eating behaviors occur more frequently in people with type 1 diabetes (T1D). Having T1D and eating disorders (T1DE) more than triples the risk of diabetic ketoacidosis and death compared to those without eating disorders. Insulin restriction involves purposely under-dosing or omitting insulin to lose weight. The primary objective was to identify the unique obstacles faced by diabetes healthcare clinicians (HCs) in their communication with patients who have suspected T1DE/insulin restriction, and HCs' educational needs and preferred approaches in working with T1DE. Semi-structured virtual interviews were conducted with diabetes HCs (<i>n</i> = 17). An inductive codebook was developed to analyze transcripts, with inter-rater reliability established by 2 coders (kappa = 0.9). Themes were developed across categories, codes, and coded segments. HCs discussed 3 themes surrounding T1DE and insulin restriction: (1) HCs felt more confident in identifying T1DE/insulin restriction through clinical indicators than in treating T1DE; (2) The majority of HCs were not confident in knowing what to say after identifying a patient with insulin restriction; and (3) HCs discussed the need for more resources and T1DE training, and provided feedback on preferred methods of education. T1DE/insulin restriction is a challenge to address and manage in diabetes clinics. More hands-on training (eg, communication workshops, standardized patient simulations, or structured educational tools) is needed for HCs to have meaningful conversations around T1DE/insulin restriction. Earlier recognition of insulin restriction and timely intervention could potentially reduce acute complications, including diabetic ketoacidosis, and improve long-term outcomes.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"750-755"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Diagnostic Conundrum: A Hemorrhagic Adrenal Mass With Discordant Radiological, Biochemical, and Pathologic Features. 诊断难题:放射学、生化和病理特征不一致的出血性肾上腺肿块。
AACE endocrinology and diabetes Pub Date : 2026-07-07 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.07.001
Rahul Atodaria, Layla Abdul Jabbar, Jhonatan Rivera-Mora, Dinh Quoc Duong, Randa Abdelmasih
{"title":"A Diagnostic Conundrum: A Hemorrhagic Adrenal Mass With Discordant Radiological, Biochemical, and Pathologic Features.","authors":"Rahul Atodaria, Layla Abdul Jabbar, Jhonatan Rivera-Mora, Dinh Quoc Duong, Randa Abdelmasih","doi":"10.1016/j.aed.2026.07.001","DOIUrl":"10.1016/j.aed.2026.07.001","url":null,"abstract":"<p><strong>Background: </strong>Adrenal incidentalomas vary in their identity, making accurate diagnosis essential for management. Interpretation of these lesions using radiology, biochemistry, or pathology can be confounded by hemorrhagic changes, medication effects, and limitations of imaging. To prevent misclassification, an integrated assessment is crucial.</p><p><strong>Case report: </strong>We present a case of a 71-year-old male with an incidentally discovered left adrenal mass that exhibited computed tomography and MRI imaging findings concerning for pheochromocytoma or adrenal malignancy.</p><p><strong>Discussion: </strong>Biochemical analysis ruled out pheochromocytoma and was suggestive of possible glucocorticoid and mineralocorticoid co-secretion, although clinical urgency of surgical resection precluded completion of confirmatory endocrinologic testing. The lesion was initially diagnosed as a benign endothelial adrenal cyst on pathologic review. Because of the discordance among the radiological, biochemical, and initial pathologic findings, an integrated histologic re-evaluation was requested. The mass was ultimately reclassified as an adrenocortical adenoma with extensive hemorrhagic and cystic changes.</p><p><strong>Conclusion: </strong>This case highlights the importance of multidisciplinary integration when evaluating adrenal lesions with confounding features and underscores how suggestive (though incomplete) biochemical evidence can appropriately drive pathological re-evaluation.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"778-782"},"PeriodicalIF":0.0,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When Weight Loss Surgery Meets Hidden Genetics: Lessons From a Case of Post-Bariatric Surgery Hypoglycemia With ABCC8 and GCK Mutation. 当减肥手术遇到隐藏的遗传学:从一例伴有ABCC8和GCK突变的减肥手术后低血糖患者的经验教训
AACE endocrinology and diabetes Pub Date : 2026-07-06 eCollection Date: 2026-09-01 DOI: 10.1016/j.aed.2026.06.012
Uchechi Adeniran, Ibrahim H Topkaya, Timothy Shope, Melih Kasap, Tuncay Delibasi, Malek El Muayed
{"title":"When Weight Loss Surgery Meets Hidden Genetics: Lessons From a Case of Post-Bariatric Surgery Hypoglycemia With <i>ABCC8</i> and <i>GCK</i> Mutation.","authors":"Uchechi Adeniran, Ibrahim H Topkaya, Timothy Shope, Melih Kasap, Tuncay Delibasi, Malek El Muayed","doi":"10.1016/j.aed.2026.06.012","DOIUrl":"10.1016/j.aed.2026.06.012","url":null,"abstract":"<p><strong>Background/objective: </strong>Postbariatric hypoglycemia is a recognized complication of Roux-en-Y gastric bypass. We report a case of refractory hypoglycemia following gastric bypass where genetic testing revealed variants that may have contributed to her presentation.</p><p><strong>Case report: </strong>A 26-year-old woman with a body mass index of 48.4 kg/m<sup>2</sup> underwent Roux-en-Y gastric bypass and achieved ∼63 kg of weight loss. Subsequently, she developed recurrent postprandial hypoglycemia with glucose values in the 2.2 to 2.8 mmol/L range, with loss of consciousness. Evaluation excluded insulinoma as a cause. Continuous glucose monitoring confirmed delayed postprandial hypoglycemia. Targeted genetic testing using a 120-gene panel identified a heterozygous pathogenic <i>ABCC8</i> variant c.1332G>T (p.Gln444His) and a <i>GCK</i> variant c.757G>A (p.Val253Ile) of uncertain significance. Sequential pharmacotherapy with acarbose +/- octreotide 50 μg sc 3 times daily + diazoxide 175 mg 3 times daily yielded only partial improvement (Fig. 1). The patient underwent an open Branco-Zorron switch procedure, after which hypoglycemic episodes decreased in frequency and severity on low-dose octreotide at 4 months of follow-up.</p><p><strong>Discussion: </strong>The identification of a genetic susceptibility in this patient suggests that latent genetic susceptibility to hypoglycemia may predispose to severe hypoglycemia when unmasked by the metabolic changes following bariatric surgery. This is especially relevant given that hyperinsulinemia is associated with weight gain.</p><p><strong>Conclusion: </strong>This case raises the possibility that preoperative genetic screening for hypoglycemia-associated variants may improve risk post-bariatric hypoglycemia stratification in bariatric surgery candidates.</p>","PeriodicalId":520949,"journal":{"name":"AACE endocrinology and diabetes","volume":"13 5","pages":"842-846"},"PeriodicalIF":0.0,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149330129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书